EDX Medical Group PLC strengthens senior team
EDX Medical Group PLC strengthens senior team
22 June 2023
EDX Medical Group PLC ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases, today announces that Dr Keti Zeka will be joining the senior management team as Head of R&D and Director of Laboratories. Dr Liam Dower will join the senior management team as Head of Quality, Regulatory Affairs & Compliance. Both will be based at the Company's laboratory and head office in Cambridge, UK.
Dr. Zeka is a highly experienced biochemist who holds a BSc and MSc in Medical Biotechnology (cum Laude) and a PhD in Chemical Engineering & Biotechnology Innovation from the University of L'Aquila, Italy. Since 2017, she has held multiple prestigious research fellowships at the University of Cambridge and University College London, in addition to her commercial experience as the PCR Team Lead at the National Covid-19 Testing Centre in Cambridge.
Dr Zeka commented:
"I'm delighted to join EDX Medical as this role provides the opportunity for me to lead a team of exceptional scientists and technologists focused on pioneering the use of digital diagnostics for the benefit of patients."
Dr Dower holds a first class B.Eng and PhD from the Department of Metallurgy & Engineering Materials, University of Strathclyde along with a postgraduate certificate in Intellectual Property management from Bournemouth University. He has previously held product development, quality and regulatory posts at Johnson & Johnson, Origin Sciences and Fluidic Analytics.
Dr Dower commented:
"I'm delighted to be able to bring my wide experience of the regulated medical device sector to EDX Medical at this exciting time in the company's growth."
Dr Mike Hudson, Chief Executive of EDX Medical Group PLC, commented:
"We are thrilled to welcome Keti and Liam, where they will play pivotal roles developing and delivering ISO-15189 accredited laboratory services and ISO 13485 accredited point of care tests for our clients in the clinical sector."
Contacts:
|
EDX Medical PLC |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 mike@edxmedical.co.uk |
|
|
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
|
|
|
|
Media House International |
|
|
Ramsay Smith (Director)
Gary McQueen (Senior Consultant) |
+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group
EDX Medical Group Plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and a 100%-owned subsidiary "Torax Biosciences Ltd" (www.toraxbiosciences.co.uk) in Ireland.
EDX Medical, provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund